

## Guidelines on Cardiac Pacing 2013 (TF27) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Auricchio Angelo	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Biologics Delivery Systems, Cordis Corporation a Johnson &amp; Johnson company : Biological Therapy (2010)</li> <li>- Biologics Delivery Systems, Cordis Corporation a J&amp;J company : Biological Therapy (2011-2012)</li> <li>- Daiichi Sankyo : Cardiac Imaging (2011)</li> <li>- Philips : Cardiac Imaging (2010)</li> <li>- Merck Sharp &amp; Dohme : Drugs (2010-2011)</li> <li>- Abbott : Implantable Cardiac Electronic Device (2010-2011-2012)</li> <li>- Medtronic : Implantable Cardiac Electronic Device (2010-2011-2012)</li> <li>- Sorin Group : Implantable Cardiac Electronic Device (2010-2011-2012)</li> <li>- St Jude Medical : Implantable Cardiac Electronic Device (2010-2011)</li> <li>- Biotronik : Implantable Cardiac Electronic Device (2010-2011-2012)</li> <li>- Impulse Dynamics : Implantable Cardiac Electronic Device (2010-2011)</li> <li>- EBR Systems : Implantable Cardiac Electronic Device (2010-2011-2012)</li> </ul> <p><b>Additional information declared for 2013 January - May:</b></p> <p>14/05/2013      no changes to declare</p>
Baron Esquivias Gonzalo	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : Anticoagulation (2010-2012)</li> <li>- Boehringer-Ingelheim : Anticoagulation (2010-2012)</li> <li>- Bristol Myers Squibb : Anticoagulation (2010)</li> <li>- Rovi : Dyslipidemia (2012)</li> </ul>

## Guidelines on Cardiac Pacing 2013 (TF27) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Bordachar Pierre	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.            - Medtronic : Pacemaker (2010-2011-2012)            No additional information for the 2013 January - May period has been submitted</p>
Boriani Giuseppe	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.            - None            - Medtronic : Pacemaker, cardioverter-defibrillators (2011-2012)</p> <p><b>Additional information declared for 2013 January - May:</b></p> <p>30/05/2013      no changes to declare</p>
Breithardt Ole-Alexander	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.            - Boston Scientific : CRT (2011-2012)            - Siemens Healthcare : Echocardiography (2011)            - GE Healthcare : Echocardiography (2011-2012)            - Boston Scientific : Speaker Fee (2010)            - Sanofi Aventis : Speaker Fee (2010)            - GE Healthcare : Speaker fees (2010)            - St Jude Medical : CRM (2012)            - St Jude Medical : CRM (2012)</p> <p>No additional information for the 2013 January - May period has been submitted</p>
Brignole Michele	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.            - Medtronic : Cardiac pacing (2012)            - Medtronic : CRM devices (2010)</p>

## Guidelines on Cardiac Pacing 2013 (TF27) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
	<p><b>Additional Information declared for 2013 January - May:</b></p> <p>15/05/2013      same relationships as last year i.e. no changes to declare</p>
Cleland John	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Antithrombotic Agents (2012)</li> <li>- Boehringer-Ingelheim : Anti-thrombotics (2010)</li> <li>- Daiichi Sankyo : Anti-thrombotics (2010-2012)</li> <li>- Bayer Healthcare : Anti-thrombotics (2010)</li> <li>- Biosense Webster : Atrial Fibrillation (2012)</li> <li>- CEPHALON : Biologicals (2011)</li> <li>- Teva Pharmaceutical Industries : Biologicals (2011)</li> <li>- BRAHMS GmbH : Biomarkers (2010-2011-2012)</li> <li>- Alere : Biomarkers (2010-2011-2012)</li> <li>- F. Hoffman La Roche Ltd : Biomarkers (2010)</li> <li>- BG medicine : Biomarkers (2011-2012)</li> <li>- Nile Therapeutics : BNP analogues (2010)</li> <li>- GE Healthcare : cardiac imaging (2012)</li> <li>- Merck Sharp &amp; Dohme : Cardiovascular Drugs (2010)</li> <li>- Medtronic : CRT (2012)</li> <li>- Novartis : CV Drugs (2010)</li> <li>- Servier : CV Drugs (2010)</li> <li>- Sanofi Aventis : CV Drugs (2010)</li> <li>- Takeda Pharmaceuticals : CV Drugs (2010)</li> </ul>

## Guidelines on Cardiac Pacing 2013 (TF27) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Cleland John	<ul style="list-style-type: none"> <li>- Boston Scientific : Devices (2010)</li> <li>- Medtronic : Devices (2010)</li> <li>- Philips : Devices (2011)</li> <li>- Sorin Group : Devices (2012)</li> <li>- St Jude Medical : Devices (2010-2011-2012)</li> <li>- Biotronik : Devices (2010)</li> <li>- Cameron Health : Devices (2010)</li> <li>- Philips : Diagnostics (2012)</li> <li>- GlaxoSmithKline : Drugs for Heart Failure (2010)</li> <li>- Amgen Inc : ESP and Myosin Activators (2010)</li> <li>- Almiral Spain : Generics (2010)</li> <li>- Amgen : Heart Failure (2012)</li> <li>- Novartis : Heart Failure (2012)</li> <li>- Pfizer : Heart failure (2012)</li> <li>- Servier : Heart Failure (2012)</li> <li>- Menarini : heart failure (2012)</li> <li>- Johnson &amp; Johnson : heart failure (2012)</li> <li>- Otsuka Pharmaceuticals Development and Commercialization (consultancy) : Heart Failure (2012)</li> <li>- Cardiomems : Heart Failure Monitoring (2012)</li> <li>- GE Healthcare : Imaging (2010)</li> <li>- Bristol Myers Squibb : Irbesartan (2010)</li> <li>- Vifor International : Iron (2010-2012)</li> <li>- Sensible Medical : Monitoring (2012)</li> <li>- F. Hoffman La Roche Ltd : Myocardial Infraction, Biomarkers (2012)</li> </ul>

## Guidelines on Cardiac Pacing 2013 (TF27) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Cleland John	<ul style="list-style-type: none"> <li>- Johnson &amp; Johnson : Nesiritide (2010)</li> <li>- Genzyme : Novel drugs (2010)</li> <li>- Danone : Nutrition (2010)</li> <li>- Bayer : Pharmaceuticals (2011)</li> <li>- Boehringer-Ingelheim : Pharmaceuticals (2011)</li> <li>- Novartis : Pharmaceuticals (2011)</li> <li>- Servier : Pharmaceuticals (2011)</li> <li>- Sanofi Aventis : Pharmaceuticals (2012)</li> <li>- GlaxoSmithKline : Pharmaceuticals (2011)</li> <li>- Menarini : Pharmaceuticals (2011)</li> <li>- Johnson &amp; Johnson : Pharmaceuticals (2011)</li> <li>- Torrent : Pharmaceuticals (2011-2012)</li> <li>- Amgen Inc : Pharmaceuticals (2011)</li> <li>- Genzyme : Pharmaceuticals (2011)</li> <li>- Merck Sharp &amp; Dohme : Pharmaceuticals (2011-2012)</li> <li>- Menarini : Ranolazine (2010)</li> <li>- Baxter : Renal Therapies (2010)</li> <li>- National Institute for Health Research : Research (2011)</li> <li>- BMBF - German Ministry of Research and Education : Research (2011)</li> <li>- Astra Zeneca : Rosuvastatin (2010)</li> <li>- Cardiomems : Sensors (2011)</li> <li>- Resmed : Sleep Apnoea (2011)</li> <li>- Baxter : Solutions (2011)</li> <li>- CEPHALON : Stem Cells (2012)</li> </ul>

## Guidelines on Cardiac Pacing 2013 (TF27) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Cleland John	<ul style="list-style-type: none"> <li>- Bosch AG Germany : Telemonitoring (2011)</li> <li>- Philips : Telemonitoring and Cardiac Imaging (2010)</li> <li>- Torrent : AGE Breakers (2010)</li> <li>- Medtronic : Devices (2010)</li> <li>- Torrent : Pharmaceuticals (2012)</li> <li>- Roche Pharma : Pharmaceuticals (2012)</li> <li>D - Research funding (departmental or institutional).               <ul style="list-style-type: none"> <li>- Biosense Webster : Ablation (2011)</li> <li>- Torrent : AGE Breaker (2010)</li> <li>- Novartis : Aliskiren and Relaxin (2010)</li> <li>- Boehringer-Ingelheim : atrial fibrillation (2010)</li> <li>- Biosense Webster : Atrial Fibrillation (2012)</li> <li>- CEPHALON : Biologicals (2011)</li> <li>- Teva Pharmaceutical Industries : Biologicals (2011)</li> <li>- BRAHMS GmbH : Biomarkers (2010-2012)</li> <li>- BRAHMS GmbH : Biomarkers (2011)</li> <li>- Alere : Biomarkers (2012)</li> <li>- Alere : Biomarkers (2010-2011)</li> <li>- BG medicine : Biomarkers (2011)</li> <li>- British Heart Foundation : Cardiovascular Medicine (2010)</li> <li>- Servier : CV Drugs (2010)</li> <li>- Amgen : Darbepoetin (2010)</li> <li>- Sorin Group : Devices (2011)</li> <li>- Biotronik : Devices (2011)</li> <li>- BG medicine : Galectin (2010)</li> </ul> </li> </ul>

## Guidelines on Cardiac Pacing 2013 (TF27) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Cleland John	<ul style="list-style-type: none"> <li>- Fondation Leducq : Genetics (2010)</li> <li>- Amgen : Heart Failure (2012)</li> <li>- Servier : Heart Failure (2012)</li> <li>- Takeda Pharmaceuticals : Heart failure services (2010)</li> <li>- Vifor International : Iron (2012)</li> <li>- Vifor International : Iron (2010)</li> <li>- Philips : Monitoring (2012)</li> <li>- NI Medical : Monitoring (2012)</li> <li>- Amgen : Pharmaceuticals (2011)</li> <li>- Bayer : Pharmaceuticals (2011)</li> <li>- Boehringer-Ingelheim : Pharmaceuticals (2011)</li> <li>- Novartis : Pharmaceuticals (2011)</li> <li>- Pfizer : Pharmaceuticals (2011)</li> <li>- Servier : Pharmaceuticals (2011)</li> <li>- Menarini : Pharmaceuticals (2011)</li> <li>- Johnson &amp; Johnson : Pharmaceuticals (2011)</li> <li>- Torrent : Pharmaceuticals (2011)</li> <li>- Vifor International : Pharmaceuticals (2011)</li> <li>- Takeda Pharmaceuticals : Pharmaceuticals (2011)</li> <li>- Merck Sharp &amp; Dohme : Pharmaceuticals (2011)</li> <li>- Galenica Vifor : Pharmaceuticals (2011)</li> <li>- Roche Diagnostics : Pharmaceuticals and Biomarkers (2011)</li> <li>- Oxford University Press : Publishing (2011)</li> <li>- National Institute for Health Research : Research (2011)</li> </ul>

## Guidelines on Cardiac Pacing 2013 (TF27) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Cleland John	<ul style="list-style-type: none"> <li>- British Heart Foundation : Research (2011)</li> <li>- Cardiomems : Sensors (2011)</li> <li>- Resmed : Sleep Apnoea (2011)</li> <li>- Philips : Telemedicine (2010)</li> <li>- Philips : Telemonitoring and Devices (2011)</li> </ul> <p><b>Additional Information declared for 2013 January - May:</b></p> <p>30/05/2013      None</p>
Deharo Jean-Claude	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : Antiarrhythmic drugs (2010-2011-2012)</li> <li>- Meda pharma : Antiarrhythmic drugs (2010-2011-2012)</li> <li>- Baxter : Antiarrhythmic drugs / Oral anticoagulants (2010-2011-2012)</li> <li>- Spectranetics : Lead extraction (2010-2011-2012)</li> <li>- Boehringer-Ingelheim : Oral anticoagulants (2010-2011-2012)</li> <li>- Boston Scientific : PMs / ICDs (2010-2011-2012)</li> <li>- Sorin Group : PMs / ICDs (2010-2011-2012)</li> <li>- St Jude Medical : PMs / ICDs (2010-2011-2012)</li> <li>- Biotronik : PMs / ICDs (2010-2011-2012)</li> <li>- Medtronic : PMs / ICDs / Loop recorders (2010-2011-2012)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Boston Scientific : PMs/ICDs (2010-2011-2012)</li> <li>- Sorin Group : PMs/ICDs (2010-2011-2012)</li> </ul>



## Guidelines on Cardiac Pacing 2013 (TF27) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Deharo Jean-Claude	<ul style="list-style-type: none"> <li>- St Jude Medical : PMs/ICDs (2010-2011-2012)</li> <li>- Medtronic : PMs/ICDs/Loop recorders (2010-2011-2012)</li> </ul> <p><b>Additional Information declared for 2013 January - May:</b></p> <p>13/05/2013      same relationships as 2012 i.e. no changes to declare</p>
Delgado Victoria	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- St Jude Medical : cardiac resynchronization therapy (2011-2012)</li> <li>- St Jude Medical : CRT-Heart failure (2010)</li> <li>- Medtronic : Valvular heart disease (2011-2012)</li> <li>- Sadra Medical : Transcatheter valve (2012)</li> </ul> <p><b>Additional Information declared for 2013 January - May:</b></p> <p>14/05/2013      There are no changes since my last up date in February 2013</p>
Elliott Perry Mark	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Shire HGT : Enzyme replacement therapy Fabry disease (2010-2011-2012)</li> <li>- Genzyme : Enzyme replacement therapy Fabry disease (2010-2011-2012)</li> <li>- Pfizer : Treatment for TTR amyloidosis (2011-2012)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Genzyme : Cardiac magnetic resonance imaging in HCM (2010-2011-2012)</li> </ul>

## Guidelines on Cardiac Pacing 2013 (TF27) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Elliott Perry Mark	<ul style="list-style-type: none"> <li>- Shire HGT : Clinical characterisation of Anderson-Fabry Disease (2010-2011-2012)</li> <li>- National Institute for Health and Clinical Excellence : Genetics of hypertrophic cardiomyopathy (2010-2011-2012)</li> <li>- British Heart Foundation : Hypertrophic cardiomyopathy (2010-2011-2012)</li> </ul> <p>No additional information for the 2013 January - May period has been submitted</p>
Gorenek Bulent	<p>None</p> <p>No additional information for the 2013 January - May period has been submitted</p>
Israel Carsten W	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : Antiarrhythmic drugs (2012)</li> <li>- BMS : New oral anticoagulant (2012)</li> <li>- Boehringer-Ingelheim : New oral anticoagulant (2012)</li> <li>- Bayer Healthcare : New oral anticoagulant (2012)</li> <li>- Boston Scientific : Pacemakers, ICDs (2011-2012)</li> <li>- Sorin Group : Pacemakers, ICDs (2011-2012)</li> <li>- St Jude Medical : Pacemakers, ICDs, CRT (2011-2012)</li> <li>- Medtronic : Pacemakers, ICDs, CRT, Remote Monitoring (2011-2012)</li> <li>- Boston Scientific : Pacemakers, ICDs, CRTs (2010)</li> <li>- Medtronic : Pacemakers, ICDs, CRTs (2010)</li> <li>- Sorin Group : Pacemakers, ICDs, CRTs (2010)</li> <li>- St Jude Medical : Pacemakers, ICDs, CRTs (2010)</li> <li>- Biotronik : Pacemakers, ICDs, CRTs (2010)</li> <li>- Biotronik : Pacemakers, ICDs, Remote Monitoring (2011-2012)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boston Scientific : ICDs (2011-2012)</li> <li>- Biotronik : ICDs (2011-2012)</li> <li>- Medtronic : ICDs, CRT, Remote Monitoring (2011-2012)</li> </ul>

## Guidelines on Cardiac Pacing 2013 (TF27) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Israel Carsten W	<ul style="list-style-type: none"> <li>- Medtronic : Pacemakers, ICDs, CRTs (2010)</li> <li>- Boston Scientific : ICDs (2010)</li> <li>- Biotronik : ICDs (2010)</li> <li>- Medtronic : ICDs, CRTDs (2010)</li> </ul> <p><b>Additional Information declared for 2013 January - May:</b></p> <p>02/06/2013      There are no changes in 2013 compared to 2012.</p>
Leclercq Christophe	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boston Scientific : CRM (2011-2012)</li> <li>- Medtronic : CRM (2011-2012)</li> <li>- Sorin Group : CRM (2011-2012)</li> <li>- St Jude Medical : CRM (2011-2012)</li> <li>- Biotronik : CRM (2011-2012)</li> <li>- General Electric : CRM (2011-2012)</li> <li>- Boston Scientific : Devices (2010)</li> <li>- Medtronic : Devices (2010)</li> <li>- Sorin Group : Devices (2010)</li> <li>- St Jude Medical : devices (2010)</li> <li>- Biotronik : Devices (2010)</li> <li>- Boehringer-Ingelheim : NOACS (2012)</li> <li>- Medtronic : devices (2010)</li> <li>- Sorin Group : devices (2010)</li> </ul>

## Guidelines on Cardiac Pacing 2013 (TF27) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Linde Cecilia	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Cardiomems : heart failure monitoring (2012)</li> <li>- Medtronic : medical devices (2010)</li> <li>- St Jude Medical : medical devices (2010)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : CRT (2011-2012)</li> <li>- Boston Scientific : medical devices (2010)</li> <li>- St Jude Medical : medical devices (2010)</li> <li>- Medtronic : medical devices (2010)</li> <li>- Medtronic : CRT (2011-2012)</li> </ul> <p><b>Additional Information declared for 2013 January - May:</b></p> <p>13/05/2013      I am not head of Dpt any more. Otherwise no Changes indicated Cecilia</p>
Mont Lluís	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- St Jude Medical : Atrial Fibrillation, Resynchronization Therapy. (2011-2012)</li> <li>- Biosense : Atrial Fibrillation. (2012)</li> <li>- Cordis : catheters (2010)</li> <li>- Boston Scientific : defibrillators, pacemakers (2010)</li> <li>- Sorin Group : Pacemakers, ICD (2010)</li> <li>- St Jude Medical : Pacemakers, ICD, catheters (2010)</li> <li>- Boston Scientific : Resynchronization Therapy. (2012)</li> <li>- Medtronic : Resynchronization Therapy. (2012)</li> </ul>

## Guidelines on Cardiac Pacing 2013 (TF27) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Mont Lluís	<ul style="list-style-type: none"> <li>- Sorin Group : Resynchronization Therapy. (2012)</li> <li>- Biotronik : Resynchronization Therapy. (2012)</li> <li>- Medtronic : ICD, pacemakers, catheters (2010)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Biosense Webster : Atrial Fibrillation (2011)</li> <li>- St. Jude Medical : Atrial Fibrillation, Resynchronization Therapy. (2012)</li> <li>- Bard : Atrial Fibrillation. (2012)</li> <li>- Biosense Webster : Atrial Fibrillation. (2012)</li> <li>- Medtronic, Boston scientific, Sorin, Cordis, St Jude : catheters, Pacemakers, ICD (2010)</li> <li>- Medtronic : Resynchronization Therapy. (2012)</li> <li>- Sorin Group : Resynchronization Therapy. (2012)</li> <li>- Biotronik : Resynchronization Therapy. (2012)</li> </ul> <p>No additional information for the 2013 January - May period has been submitted</p>
Padeletti Luigi	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boston Scientific : cardiac devices (2012)</li> <li>- Medtronic : cardiac devices (2012)</li> <li>- Sorin Group : Cardiac devices (2012)</li> <li>- Biotronik : cardiac devices (2012)</li> <li>- St Jude : cardiac devices (2012)</li> <li>- Boston Scientific : device (2010)</li> <li>- Medtronic : device (2010)</li> <li>- Sorin Group : device (2010)</li> <li>- St Jude Medical : device (2010)</li> <li>- Biotronik : device (2010)</li> <li>- Boston Scientific : Devices (2011)</li> </ul>

## Guidelines on Cardiac Pacing 2013 (TF27) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Padeletti Luigi	<ul style="list-style-type: none"> <li>- Medtronic : Devices (2011)</li> <li>- Sorin Group : Devices (2011)</li> <li>- St Jude Medical : Devices (2011)</li> <li>- Biotronik : Devices (2011)</li> <li>- Medico : Devices (2011)</li> <li>- Medtronic : device (2010)</li> <li>- Sanofi Aventis : drugs (2010)</li> </ul> <p><b>Additional Information declared for 2013 January - May:</b></p> <p>10/06/2013      no changes to declare</p>
Sutton Richard	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : All implantable Devices (2010-2011)</li> <li>- St Jude Medical : All implantable Devices (2011)</li> <li>- Medtronic : Device Therapy and Scientific Writing (2012)</li> <li>- St Jude Medical : Device Therapy and Scientific Writing (2012)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Medtronic : Implantable loop recorders and external devices (2010-2011)</li> <li>- Medtronic : Syncope (2012)</li> </ul> <p><b>Additional Information declared for 2013 January - May:</b></p> <p>30/05/2013      I have no additional interests to declare compared with 2012</p>

## Guidelines on Cardiac Pacing 2013 (TF27) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Vardas Panagiotis	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : Dronedarone (2010)</li> <li>- Bayer : Honoraria for participation in "ASP Alliance" and "SPAF Advisory Board". Speaker fees. (2011)</li> <li>- Boehringer-Ingelheim : Honorarium for participation in Advisory Board. Speaker fees (2011)</li> <li>- Menarini : Honorarium for participation in Ranolazine Advisory Board (2011)</li> <li>- Servier : Ivabradine (2010)</li> <li>- Boehringer-Ingelheim : SPAF Academy (2010)</li> <li>- Servier : Speaker and article-writing fees (2011-2012)</li> <li>- Bayer : Speaker fees (2012)</li> <li>- Boehringer-Ingelheim : Speaker fees (2012)</li> <li>- Menarini : Speaker fees (2012)</li> <li>- Medtronic : Consultancy fee (2011-2012)</li> <li>- Bristol Myers Squibb : Honorarium (2011-2012)</li> <li>- Bayer : Speaker fee (2011-2012)</li> <li>- Boehringer-Ingelheim : Speaker fees (2012)</li> <li>- Boehringer-Ingelheim : Speaker fees and honoraria (2011)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Amgen : ATOMIC AHF study (institutional) (2011)</li> <li>- Novartis : CANTOS study (institutional) (2011)</li> <li>- Astra Zeneca : Epidemiology study (2010)</li> <li>- Sanofi Aventis : Epidemiology study (2010)</li> <li>- Servier : Ivabradine (2010)</li> <li>- Medtronic : MORE CARE study (institutional) (2011)</li> <li>- Medtronic : Pacemakers and ICDs (2010)</li> </ul>

## Guidelines on Cardiac Pacing 2013 (TF27) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Vardas Panagiotis	<ul style="list-style-type: none"> <li>- Servier : SIGNIFY study (institutional) (2011)</li> <li>- Servier : SIGNIFY study (institutional) (2012)</li> </ul> <p><b>Additional Information declared for 2013 January - May:</b></p> <p>22/05/2013      Same relationships as 2012 i.e. no changes to declare</p>

This table represents the relevant relationships of the above experts with Industries and other entities that were reported to us at the time of publication of the Guidelines.



## Guidelines on Cardiac Pacing 2013 (TF27) - Doc Reviewers

Expert	Type of Relationship with Industry
Aliyev Farid	None
Badano Luigi Paolo	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Edwards Lifesciences : Clinical Event Committee member (2011-2012)</li> <li>- Sorin Group : Consultancy (2011-2012)</li> <li>- GE Healthcare : Ultrasound (2011-2012)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- GE Healthcare : Ultrasound (2012)</li> </ul> <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> <li>- GE Healthcare : Ultrasound (2011-2012)</li> </ul> <p><b>Additional Information declared for 2013 January - May:</b></p> <p>28/05/2013      No changes in my financial interests or positions</p>
Baensch Dietmar	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : Anticoagulation (2012)</li> <li>- Boehringer-Ingelheim : Atrial Fibrillation (2011)</li> <li>- Biosense Webster : Catheterablation (2011)</li> <li>- Medtronic : ICD (2012)</li> <li>- St Jude Medical : ICD (2012)</li> <li>- Biotronik : ICD (2012)</li> <li>- Medtronic : Implantable Devices (2011)</li> <li>- Biotronik : Implantable Devices (2011)</li> </ul>

## Guidelines on Cardiac Pacing 2013 (TF27) - Doc Reviewers

Expert	Type of Relationship with Industry
Baensch Dietmar	<p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Biosense Webster : Ablation (2012)</li> <li>- Boston Scientific : Catheter Ablation (2011)</li> <li>- Boston Scientific : ICD (2011)</li> <li>- Medtronic : ICD (2011-2012)</li> <li>- Biotronik : ICD (2011-2012)</li> </ul> <p><b>Additional Information declared for 2013 January - May:</b></p> <p>14/05/2013      All information are up to date. DB</p>
Baumgartner Helmut	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Actelion : Bosentan for PAH treatment in congenital heart disease (2012)</li> <li>- Edwards Lifesciences : transcatheter valve implantation (2012)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Actelion : Bosentan for PAH treatment in congenital heart disease (2012)</li> <li>- Edwards Lifesciences : transcatheter valve implantation (2012)</li> </ul> <p><b>Additional Information declared for 2013 January - May:</b></p> <p>13/05/2013      no changes compared to 2012</p>
Blomstrom-Lundqvist Carina	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : AF (2011-2012)</li> </ul>

## Guidelines on Cardiac Pacing 2013 (TF27) - Doc Reviewers

Expert	Type of Relationship with Industry
Blomstrom-Lundqvist Carina	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : AF (2012)</li> <li>- Biotronik : Arrhythmia (2011-2012)</li> <li>- Medtronic : ICD, AF (2011)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Medtronic : AF (2011-2012)</li> <li>- Atricure : AF (2011)</li> <li>- Biotronik : Arrhythmias (2011-2012)</li> </ul> <p><b>Additional Information declared for 2013 January - May:</b></p> <p>16/05/2013      Research support from Cardiome lowest level</p>
Bsata Walid	<p>None</p> <p><b>Additional Information declared for 2013 January - May:</b></p> <p>23/05/2013      no new changes</p>
Buser Peter	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- None</li> <li>- Novartis : Imaging (2011)</li> </ul> <p><b>Additional Information declared for 2013 January - May:</b></p>

## Guidelines on Cardiac Pacing 2013 (TF27) - Doc Reviewers

Expert	Type of Relationship with Industry
	<p>14/05/2013 'same relationships as 2012 i.e. no changes to declare':</p>
Charron Philippe	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - None</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Heart failure and CAD (2012) - Shire HGT : Lysosomal diseases (2012) - Genzyme : Lysosomal diseases (2011-2012) - Actelion : Pulmonary hypertension (2011)</p> <p><b>Additional Information declared for 2013 January - May:</b></p> <p>13/05/2013 List of the ESC bodies you are members: add "Working Group Myocardial &amp; pericardial diseases" Other relationships are similar as in 2012</p>
Daubert Jean-Claude	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : Antithrombotics (2011) - Medtronic : CRT (2012) - Sorin Group : CRT (2012) - St Jude Medical : CRT (2012) - Boehringer-Ingelheim : Dabigatran (2012) - Sanofi Aventis : Dronedarone (2011) - Medtronic : Implantable devices (2011)</p>

## Guidelines on Cardiac Pacing 2013 (TF27) - Doc Reviewers

Expert	Type of Relationship with Industry
Daubert Jean-Claude	<ul style="list-style-type: none"> <li>- Sorin Group : Implantable devices (2011)</li> <li>- St Jude Medical : Implantable devices (2011)</li> <li>- EBR Systems : Implantable devices (2011)</li> <li>- Heart.org : Interviews (2011)</li> <li>- Novartis : Medical education (2011)</li> <li>- Bristol Myers Squibb : NA (2012)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : CRT (2012)</li> <li>- Medtronic : iMPLANTABLE DEVICES (2011)</li> <li>- Medtronic : CRT (2012)</li> </ul> <p><b>Additional Information declared for 2013 January - May:</b></p> <p>13/05/2013      No change</p>
Dobreanu Dan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Abbott : cardiovascular drugs (2012)</li> <li>- Astra Zeneca : cardiovascular drugs (2012)</li> <li>- Boehringer-Ingelheim : cardiovascular drugs (2012)</li> <li>- Pfizer : cardiovascular drugs (2012)</li> <li>- Servier : cardiovascular drugs (2011-2012)</li> <li>- Berlin Chemie AG : cardiovascular drugs (2012)</li> <li>- Servier : cardiovascular drugs (2011)</li> </ul>

## Guidelines on Cardiac Pacing 2013 (TF27) - Doc Reviewers

Expert	Type of Relationship with Industry
	<p><b>Additional Information declared for 2013 January - May:</b></p> <p>14/05/2013      Same relationships as 04/03/2013, no changes to declare</p>
Faerstrand Svein	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : Speakers fees (2011)</li> <li>- Medtronic : Speakers fees (2012)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boston Scientific, Medtronic, St Jude : Pacing and ICD trials (2011)</li> <li>- Medtronic, Boston Scientific, St Jude Medical, Biotronic : Pacing and ICD trials (2012)</li> </ul> <p><b>Additional Information declared for 2013 January - May:</b></p> <p>13/05/2013      Same relationships as 2012 i.e. no changes to declare</p>
Hasdai David	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- None</li> <li>- Boehringer-Ingelheim : Pradaxa (2012)</li> <li>- Bayer : Rivaroxiban (2012)</li> <li>- Astra Zeneca : Ticagrelor (2012)</li> </ul> <p><b>Additional Information declared for 2013 January - May:</b></p> <p>14/05/2013      none</p>

## Guidelines on Cardiac Pacing 2013 (TF27) - Doc Reviewers

Expert	Type of Relationship with Industry
Hoes Arno	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - None</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Various : I chair a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2012)</p> <p>- Zorg binnen Bereik : Member of project team of Zorg Binnen Bereik, a Dutch Achmea (health insurance company) and Philips sponsored research program to test patient e-health platforms in patients with chronic disease (heart failure, COPD and diabetes) (2012)</p> <p>- Boehringer-Ingelheim : Member Scientific Committee of Zorro; a research program sponsored by an unrestricted grant from Boehringer-Ingelheim with the aim to improve anticoagulant care in the Netherlands (2012)</p> <p>D - Research funding (departmental or institutional). - I am the director of a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2012)</p> <p><b>Additional Information declared for 2013 January - May:</b></p> <p>03/06/2013      no changes to declare</p>
Kirchhof Paulus	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - BMS : cardiovascular (2011-2012)</p>

## Guidelines on Cardiac Pacing 2013 (TF27) - Doc Reviewers

Expert	Type of Relationship with Industry
Kirchhof Paulus	<ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : cardiovascular (2011-2012)</li> <li>- Daiichi Sankyo : cardiovascular (2011-2012)</li> <li>- Medtronic : cardiovascular (2011-2012)</li> <li>- Pfizer : cardiovascular (2012)</li> <li>- St Jude Medical : cardiovascular (2011-2012)</li> <li>- Sanofi Aventis : cardiovascular (2011)</li> <li>- Sanofi Aventis : cardiovascular (2012)</li> <li>- Meda pharma : cardiovascular (2011-2012)</li> <li>- Merck Sharp &amp; Dohme : cardiovascular (2011-2012)</li> <li>- Otsuka Pharmaceuticals Development and Commercialization (consultancy) : cardiovascular (2011-2012)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : cardiovascular (2012)</li> <li>- Bayer Healthcare : cardiovascular (2012)</li> <li>- Portola Pharmaceuticals : cardiovascular (2012)</li> <li>- BMS / Pfizer alliance : cardiovascular (2012)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- St Jude Medical : cardiovascular (2011-2012)</li> <li>- Sanofi Aventis : cardiovascular (2011-2012)</li> <li>- Meda pharma : cardiovascular (2012)</li> <li>- Meda pharma : cardiovascular (2011)</li> </ul> <p><b>Additional Information declared for 2013 January - May:</b></p> <p>14/05/2013      Consulting fees and honoraria  3M Medica  MEDA Pharma  AstraZeneca  Bayer Healthcare</p>



## Guidelines on Cardiac Pacing 2013 (TF27) - Doc Reviewers

Expert	Type of Relationship with Industry
	<p>           Biosense Webster            Boehringer Ingelheim            Daiichi-Sankyo            German Cardiac Society            MEDA Pharma            Medtronic            Merck            MSD            Otsuka Pharma            Pfizer / BMS            sanofi            Servier            Siemens            TAKEDA         </p> <p>           In addition, I have received travel support for meetings from the European Society of Cardiology (ESC), the European Heart Rhythm Association (EHRA), a registered branch of ESC, and from the German Atrial Fibrillation Competence NETwork (AFNET)         </p> <p>           Research Grants            3M Medica / MEDA Pharma            Cardiovascular Therapeutics            Medtronic            OMRON            SANOFI            St. Jude Medical            German Federal Ministry for Education and Research (BMBF)            Fondation Leducq            German Research Foundation (DFG)            European Union (EU)         </p>

## Guidelines on Cardiac Pacing 2013 (TF27) - Doc Reviewers

Expert	Type of Relationship with Industry
Le Heuzey Jean-Yves	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : antiarrhythmic (2011-2012)</li> <li>- Sanofi Aventis : antiarrhythmic (2011-2012)</li> <li>- Meda pharma : antiarrhythmic (2011-2012)</li> <li>- Pierre-Fabre : antiarrhythmic (2011)</li> <li>- Merck Sharp &amp; Dohme : antiarrhythmic (2011-2012)</li> <li>- Bayer : anticoagulant (2011-2012)</li> <li>- BMS : anticoagulant (2011-2012)</li> <li>- Boehringer-Ingelheim : anticoagulant (2011-2012)</li> <li>- Daiichi Sankyo : anticoagulant (2011-2012)</li> <li>- GSK : anticoagulant (2012)</li> <li>- Medtronic : PM/ICD (2011)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : antiarrhythmic (2011-2012)</li> <li>- Daiichi Sankyo : anticoagulant (2011-2012)</li> </ul> <p><b>Additional Information declared for 2013 January - May:</b></p> <p>13/05/2013      same relationships as 2012 i.e. no changes to declare</p>
Mavrakis Iraklis	<p>None</p> <p>No additional information for the 2013 January - May period has been submitted</p>
McDonagh Theresa	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Vifor International : Ferrinject (2012)</li> </ul>

## Guidelines on Cardiac Pacing 2013 (TF27) - Doc Reviewers

Expert	Type of Relationship with Industry
McDonagh Theresa	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.            - Servier : Ivabridine (2012)            No additional information for the 2013 January - May period has been submitted</p>
Merino Jose Luis	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.            - St Jude Medical : Atrial fibrillation (2011-2012)            - Magnetecs : Atrial fibrillation (2012)            - Magnetecs : CGCI Magnetic Remote Navigation System (2011)            - Boston Scientific : Defibrillators (2011-2012)            - Biotronik : Defibrillators (2012)            - Sanofi Aventis : Dronedarone (2011-2012)            - Bard : EP catheters (2012)            - Merck Sharp &amp; Dohme : Vernakalant (2011-2012)</p> <p>D - Research funding (departmental or institutional).            - Magnetecs : CGCI Magnetic Remote Navigation System (2012)            - Magnetecs : CGCI Magnetic Remote Navigation System (2011)            - Boston Scientific : Defibrillators (2011-2012)            - Sorin Group : Defibrillators (2011-2012)</p> <p>E - Research funding (personal).            - Sanofi Aventis : Celivarone (2011)            - Bayer : Edoxaban (2012)            - Daiichi Sankyo : Edoxaban (2011)            - Sanofi Aventis : Idraparinux (2011)            - Sanofi Aventis : Ranolazine (2012)            - Bayer : Rivaroxaban (2011)</p> <p><b>Additional Information declared for 2013 January - May:</b></p>

## Guidelines on Cardiac Pacing 2013 (TF27) - Doc Reviewers

Expert	Type of Relationship with Industry
	<p>15/05/2013 Daichii-Sankyo. Area: atrial fibrillation. Advisory Board fees. Sorin Group. Area: Cardiac Resynchronization. Advisory Board fees.</p>
Nawar Moustafa	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Antihypertensive, Hypolipaemic drugs (2012)</li> <li>- Novartis : Antihypertensive, Hypolipaemic drugs (2012)</li> <li>- Sanofi Aventis : Antihypertensive, Hypolipaemic drugs (2012)</li> <li>- Menarini : Antihypertensive, Hypolipaemic drugs (2012)</li> <li>- Merck Sharp &amp; Dohme : Antihypertensive, Hypolipaemic drugs (2012)</li> <li>- Astra Zeneca : hypercholesterolemia (2011)</li> </ul> <p><b>Additional Information declared for 2013 January - May:</b></p> <p>20/05/2013 Nothing new to declare.</p>
Nielsen Jens Cosedis	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : implantable devices (2011-2012)</li> <li>- St Jude Medical : implantable devices (2011)</li> <li>- Biotronik : implantable devices (2011)</li> <li>- Boston Scientific : implantable devices (2011)</li> <li>- Medtronic : implantable devices (2011)</li> <li>- Biotronik : implantable devices (2011)</li> <li>- Biosense Webster : Catheter ablation of atrial fibrillation. Grant for the MANTRA-PAF trial (2012)</li> </ul>

## Guidelines on Cardiac Pacing 2013 (TF27) - Doc Reviewers

Expert	Type of Relationship with Industry
	<p><b>Additional Information declared for 2013 January - May:</b></p> <p>23/05/2013      No changes from the last DOI submitted in February 2013</p>
Pieske Burkert Mathias	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Anticoagulation (2011-2012)</li> <li>- Menarini : Coronary artery disease (2011)</li> <li>- Novartis : Heart Failure (2011-2012)</li> <li>- Servier : Heart Failure (2012)</li> <li>- Bayer Healthcare : Heart Failure, Pulmonary Hypertension (2012)</li> <li>- Impulse Dynamics : Pacemakers (2012)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Medtronic : Device therapy (2012)</li> <li>- Medtronic : Device therapy (2011)</li> <li>- Bayer Healthcare : Heart Failure (2011-2012)</li> </ul> <p><b>Additional Information declared for 2013 January - May:</b></p>
Poposka Lidija	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- None</li> <li>- Servier : Principal Inversigator in SIGNIFY study (2012)</li> </ul> <p><b>Additional Information declared for 2013 January - May:</b></p>

## Guidelines on Cardiac Pacing 2013 (TF27) - Doc Reviewers

Expert	Type of Relationship with Industry
	15/05/2013 No changes to declare
Ruschitzka Frank	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Biotronik : Devices (2011-2012)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Drugs (2011-2012)</p> <p>C - Receipt of royalties for intellectual property. - Cardioentis : Drugs (2011-2012)</p> <p>D - Research funding (departmental or institutional). - Pfizer : Drugs (2011-2012)</p> <p>No additional information for the 2013 January - May period has been submitted</p>
Tendera Michal	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer : Aspirin, Rivaroxaban (2012) - Amgen : Darbopietin (2012) - Servier : Ivabradine, Phase II investigational products (2012)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Ivabradine, Phase II investigational products (2012)</p> <p><b>Additional Information declared for 2013 January - May:</b></p> <p>13/05/2013 No new info.</p>
Van Gelder Isabelle C	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - None</p>

## Guidelines on Cardiac Pacing 2013 (TF27) - Doc Reviewers

Expert	Type of Relationship with Industry
Van Gelder Isabelle C	<ul style="list-style-type: none"> <li>- Bayer : atrial fibrillation (2011)</li> <li>- Boehringer-Ingelheim : atrial fibrillation (2011)</li> <li>- Merck Sharp &amp; Dohme : atrial fibrillation (2011)</li> <li>- Medtronic : atrial fibrillation and heart failure (2011)</li> <li>- Biotronik : atrial fibrillation and heart failure (2011)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- BMS : AF (2012)</li> <li>- Boehringer-Ingelheim : AF (2012)</li> <li>- Medtronic : AF and CRT (2012)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Medtronic : atrial fibrillation and heart failure research (2011-2012)</li> <li>- Astra Zeneca : atrial fibrillation research (2011-2012)</li> <li>- Bayer : atrial fibrillation research (2011-2012)</li> <li>- Boehringer-Ingelheim : atrial fibrillation research (2011-2012)</li> <li>- Boston Scientific : atrial fibrillation research (2011-2012)</li> <li>- St Jude Medical : atrial fibrillation research (2011-2012)</li> <li>- Biotronik : atrial fibrillation research (2011-2012)</li> <li>- Sanofi Aventis : atrial fibrillation research (2011)</li> </ul> <p><b>Additional Information declared for 2013 January - May:</b></p> <p>21/05/2013      same relationships as last year i.e. no changes to declare</p>

## Guidelines on Cardiac Pacing 2013 (TF27) - Doc Reviewers

Expert	Type of Relationship with Industry
Wilson Carol	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : Devices (2011-2012)</li> <li>- Philips : Information Systems (2011-2012)</li> <li>- St Jude Medical : Intravascular diagnostics (2011)</li> <li>- GSK : Pulmonary Arterial Hypertension (2012)</li> <li>- Actelion : Pulmonary Hypertension (2011-2012)</li> </ul> <p><b>Additional Information declared for 2013 January - May:</b></p> <p>28/05/2013      No new financial interests</p>

This table represents the relevant relationships of the above experts with Industries and other entities that were reported to us at the time of publication of the Guidelines.



## Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Achenbach Stephan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Siemens Healthcare : CT (2012)</li> <li>- Servier : Imaging (2012)</li> <li>- Guerbet : Imaging (2012)</li> </ul> <p><b>Additional Information declared 'XYWUfYX'Zf'&amp;\$%'&gt;Ubi Ufmi! 'A Um</b></p> <p>14/05/2013      Same relationships as last year, nothing new to declare.</p>
Baumgartner Helmut	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Actelion : Bosentan for PAH treatment in congenital heart disease (2012)</li> <li>- Edwards Lifesciences : transcatheter valve implantation (2012)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Actelion : Bosentan for PAH treatment in congenital heart disease (2012)</li> <li>- Edwards Lifesciences : transcatheter valve implantation (2012)</li> </ul> <p><b>Additional Information declared 'XYWUfYX'Zf'&amp;\$%'&gt;Ubi Ufmi! 'A Um</b></p> <p>13/05/2013      no changes compared to 2012</p>
Bax Jeroen	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- None</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Servier : Farma (2012)</li> </ul>

## Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Bax Jeroen	<ul style="list-style-type: none"> <li>- Edwards Lifesciences : Heart Valves (2012)</li> <li>- GE Healthcare : Imaging (2012)</li> <li>- Lantheus Inc : Imaging (2012)</li> <li>- Boston Scientific : Pacing (2012)</li> <li>- Medtronic : Pacing (2012)</li> <li>- St Jude Medical : Pacing (2012)</li> <li>- Biotronik : Pacing (2012)</li> </ul> <p><b>Additional Information declared 'XYWUFYX'Zf'&amp;\$%'&gt;Ubi Ufmi! 'A Um</b></p> <p>23/06/2013      Nothing has changed</p>
Bueno Hector	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Aspirin, rivaroxaban (2012)</li> <li>- Roche Pharma : Dalcetrapib (2012)</li> <li>- Novartis : Heart Failure and elinogrel (2012)</li> <li>- Daiichi Sankyo : Prasugrel (2012)</li> <li>- Eli Lilly : Prasugrel (2012)</li> <li>- Astra Zeneca : Ticagrelor (2012)</li> </ul> <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Ticagrelor (2012)</li> </ul> <p><b>Additional Information declared 'XYWUFYX'Zf'&amp;\$%'&gt;Ubi Ufmi! 'A Um</b></p> <p>14/05/2013      No additional information to disclose in addition to my February 2013 disclosure</p>

## Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Deaton M Christi	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - None</p> <p>D - Research funding (departmental or institutional). - Novo-Nordisk : patients with heart failure and diabetes (2012)</p> <p><b>Additional Information declared</b></p> <p>13/05/2013 Funding from Novo Nordisk has ended, no other changes to report</p> <p>13/05/2013 no other new information</p>
Erol Cetin	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - None</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Perindopril (2012) - Menarini : Trandolapril (2012)</p> <p>C - Receipt of royalties for intellectual property. - Astra-Zeneca : Ticagrelor (2012)</p> <p><b>Additional Information declared</b></p> <p>13/05/2013 Only the product of Menarini should be Olmesartan. That is all I can change.</p>

## Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Fagard Robert	<p>None</p> <p><b>Additional Information declared 'XYWUFYX'Zf'&amp;\$%'&gt;Ubi Ufmi! 'A Um</b></p> <p>03/06/2013      No changes to declare</p>
Ferrari Roberto	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Anticoagulant and diabetes. Dagabitran (2012)</li> <li>- Medical Trials Analysis : Consultant in Clinical Trials (2012)</li> <li>- Servier : Myocardial ischemia and heart failure. Perindopril, ivabradine, amlodipine, trimetazidine (2012)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Schering-Plough : Anti-platelet agent TRACER (2012)</li> <li>- Fondazione Salvatore Maugeri : General (2012)</li> <li>- Servier : Perindopril, ivabradine, amlodipine CLARifY and SIGNifY (2012)</li> </ul> <p><b>Additional Information declared 'XYWUFYX'Zf'&amp;\$%'&gt;Ubi Ufmi! 'A Um</b></p> <p>14/05/2013      No new information</p>
Hasdai David	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- None</li> <li>- Boehringer-Ingelheim : Pradaxa (2012)</li> <li>- Bayer : Rivaroxiban (2012)</li> </ul>

## Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
<p>Hasdai David</p>	<p>- Astra Zeneca : Ticagrelor (2012)</p> <p><b>Additional Information declared 'XYWUFYX'Zf'&amp;\$%'&gt;Ubi Ufmi! 'A Um</b></p> <p>14/05/2013      none</p>
<p>Hoes Arno</p>	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - None</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Various : I chair a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2012)</p> <p>- Zorg binnen Bereik : Member of project team of Zorg Binnen Bereik, a Dutch Achmea (health insurance company) and Philips sponsored research program to test patient e-health platforms in patients with chronic disease (heart failure, COPD and diabetes) (2012)</p> <p>- Boehringer-Ingelheim : Member Scientific Committee of Zorro; a research program sponsored by an unrestricted grant from Boehringer-Ingelheim with the aim to improve anticoagulant care in the Netherlands (2012)</p> <p>D - Research funding (departmental or institutional). - I am the director of a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2012)</p> <p><b>Additional Information declared 'XYWUFYX'Zf'&amp;\$%'&gt;Ubi Ufmi! 'A Um</b></p> <p>03/06/2013      no changes to declare</p>

## Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Kirchhof Paulus	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- BMS : cardiovascular (2012)</li> <li>- Boehringer-Ingelheim : cardiovascular (2012)</li> <li>- Daiichi Sankyo : cardiovascular (2012)</li> <li>- Medtronic : cardiovascular (2012)</li> <li>- Pfizer : cardiovascular (2012)</li> <li>- St Jude Medical : cardiovascular (2012)</li> <li>- Sanofi Aventis : cardiovascular (2012)</li> <li>- Meda pharma : cardiovascular (2012)</li> <li>- Merck Sharp &amp; Dohme : cardiovascular (2012)</li> <li>- Otsuka Pharmaceuticals Development and Commercialization (consultancy) : cardiovascular (2012)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : cardiovascular (2012)</li> <li>- Bayer Healthcare : cardiovascular (2012)</li> <li>- Portola Pharmaceuticals : cardiovascular (2012)</li> <li>- BMS / Pfizer alliance : cardiovascular (2012)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- St Jude Medical : cardiovascular (2012)</li> <li>- Sanofi Aventis : cardiovascular (2012)</li> <li>- Meda pharma : cardiovascular (2012)</li> </ul> <p><b>Additional Information declared</b></p> <p>14/05/2013      Consulting fees and honoraria</p>

Expert	Type of Relationship with Industry
	<p>           3M Medica            MEDA Pharma            AstraZeneca            Bayer Healthcare            Biosense Webster            Boehringer Ingelheim            Daiichi-Sankyo            German Cardiac Society            MEDA Pharma            Medtronic            Merck            MSD            Otsuka Pharma            Pfizer / BMS            sanofi            Servier            Siemens            TAKEDA         </p> <p>           In addition, I have received travel support for meetings from the European Society of Cardiology (ESC), the European Heart Rhythm Association (EHRA), a registered branch of ESC, and from the German Atrial Fibrillation Competence NETwork (AFNET)         </p> <p>           Research Grants            3M Medica / MEDA Pharma            Cardiovascular Therapeutics            Medtronic            OMRON            SANOFI            St. Jude Medical            German Federal Ministry for Education and Research (BMBF)         </p>

## Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
	<p>Fondation Leducq German Research Foundation (DFG) European Union (EU)</p>
Knuuti Juhani	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Lantheus Inc : Perfusion imaging tracer development (2012)</p> <p>D - Research funding (departmental or institutional). - Servier : Vascular inflammation (2012) - Athera : vascular inflammation (2012)</p> <p>No additional information for the 2013 January - May period has been submitted</p>
Kolh Philippe H	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Antiplatelet agents (2012) - Regado Biosciences : Antithrombotic agents (2012)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Merck Sharp &amp; Dohme : Antistaphylococcic vaccine (2012)</p> <p>D - Research funding (departmental or institutional). - Edwards Lifesciences : Cardiac valves (2012) - Medtronic : Cardiac valves (2012) - St Jude Medical : Cardiac valves (2012) - Boston Scientific : Coronary stents (2012) - Siemens Healthcare : Medical imaging (2012) - Johnson &amp; Johnson : Thoracoscopic devices (2012)</p> <p><b>Additional Information declared</b></p> <p>15/05/2013      same relationships as 2012 i.e. no changes to declare</p>



## Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Lancellotti Patrizio	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boston Scientific : Heart Failure (2012)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Brilique (2012) - Servier : Coversyl (2012) - Abbott Vascular : MitraClip (2012)</p> <p>No additional information for the 2013 January - May period has been submitted</p>
Linhart Ales	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Arterial hypertension (2012) - Boehringer-Ingelheim : Arterial hypertension, atrial fibrillation (2012) - GlaxoSmithKline : Atherosclerosis (2012) - Merck Sharp &amp; Dohme : Dyslipidemia (2012) - Bayer Schering Pharma : Dyslipidemia, pulmonary hypertension, atrial fibrillation (2012) - Shire HGT : Fabry disease (2012) - Genzyme : Fabry disease (2012) - Actelion : Pulmonary hypertension (2012)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Shire HGT : Fabry disease (2012)</p> <p>No additional information for the 2013 January - May period has been submitted</p>
Nihoyannopoulos Petros	<p>None</p> <p>No additional information for the 2013 January - May period has been submitted</p>
Piepoli Massimo Francesco	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Chiesi Pharma : Anti-dyslipidemic therapy (2012)</p> <p><b>Additional Information declared</b></p> <p>13/05/2013 'same relationships as 2012 i.e. no changes to declare':</p>

## Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Ponikowski Piotr	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- BMS : anticoagulant (2012)</li> <li>- Boehringer-Ingelheim : anticoagulant (2012)</li> <li>- Respicardia : anticoagulant (2012)</li> <li>- Abbott Vascular : devices (2012)</li> <li>- Amgen : heart failure (2012)</li> <li>- Novartis : heart failure (2012)</li> <li>- Johnson &amp; Johnson : heart failure (2012)</li> <li>- Bayer Healthcare : heart failure (2012)</li> <li>- Vifor Pharma ltd : heart failure (2012)</li> <li>- Corthera : heart failure (2012)</li> <li>- Coridea : heart failure (2012)</li> <li>- Pfizer : heart failure, anticoagulant (2012)</li> <li>- Servier : heart failure, coronary artery disease (2012)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Vifor Pharma ltd : heart failure (2012)</li> </ul> <p><b>Additional Information declared</b></p> <p>14/05/2013      update to DOI 2012:                          - Abbott Vascular</p>

## Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Sirnes Per Anton	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - None</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - NORMA on behalf of Janssen Cilag : Invest fee CANVAS study (2012) - Quintiles on behalf of Novartis : Investigator fee CANTOS study (2012) - GlaxoSmithKline : Investigator fee HZC113108 and LPL100601 studies (2012) - Sticeres/InterACT on behalf of Servier : Investigator Fee SIGNIFY study (2012) - Merck Sharp &amp; Dohme : Investigator fee HPS2-THRIVE STUDY (2012) - Boehringer Ingelheim : Investigator Fee Relyable study (2012) - Schering-Plough : Investigator fee TRA2P-TIMI50 study (2012)</p> <p><b>Additional Information declared</b></p>
Tamargo Juan Luis	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - sanofi-aventis : Dronedarone-antiarrhythmic agent (2012)</p> <p>E - Research funding (personal). - Astra -Zeneca Foundation (NON-PROFIT FOUNDATION). two years Unrestricted Grant : None (2012)</p> <p>No additional information for the 2013 January - May period has been submitted</p>
Tendera Michal	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer : Aspirin, Rivaroxaban (2012) - Amgen : Darbopietin (2012) - Servier : Ivabradine, Phase II investigational products (2012)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Ivabradine, Phase II investigational products (2012)</p>

## Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
	<p><b>Additional Information declared:</b></p> <p>13/05/2013      No new info.</p>
Torbicki Adam	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Cardiomems : implanted pulmonary artery pressure sensor (2012)</li> <li>- United Therapeutics : Pulmonary arterial hypertension (2012)</li> <li>- GSK : pulmonary arterial hypertension - ambrisentan (2012)</li> <li>- Actelion : pulmonary arterial hypertension - macitentan, selexipag (2012)</li> <li>- Lilly : pulmonary arterial hypertension - tadalafil (2012)</li> <li>- AOP : Pulmonary arterial hypertension - treprostinil (2012)</li> <li>- Bayer Healthcare : pulmonary arterial hypertention - iloprost, riociguat, VTE - xarelto (2012)</li> <li>- Bristol Myers Squibb : thromboembolic disease - Apixaban (2012)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Pulmonary hypertension (2012)</li> <li>- Sanofi Aventis : Thromboembolic disease (2012)</li> </ul> <p>No additional information for the 2013 January - May period has been submitted</p>
Wijns William	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- None</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Biosensors : device (2012)</li> <li>- Boston Scientific : device (2012)</li> <li>- Edwards Lifesciences : device (2012)</li> <li>- Medtronic : device (2012)</li> <li>- St Jude Medical : device (2012)</li> </ul>

## Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Wijns William	<ul style="list-style-type: none"> <li>- Biotronik : device (2012)</li> <li>- Terumo Inc : device (2012)</li> <li>- Abbott Vascular : device (2012)</li> <li>- Cordis : device (2012)</li> <li>- Orbus Nech : device (2012)</li> <li>- MICELL : device (2012)</li> <li>- Vessix : device (2012)</li> <li>- Tryton : device (2012)</li> <li>- GlaxoSmithKline : drug (2012)</li> <li>- Astra Zeneca : pharma (2012)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Cardio3 Biosciences : cell therapy (2012)</li> <li>- Boston Scientific : device (2012)</li> <li>- Medtronic : device (2012)</li> <li>- St Jude Medical : device (2012)</li> <li>- Biotronik : device (2012)</li> <li>- Abbott Laboratories : device (2012)</li> <li>- MICELL : device (2012)</li> <li>- Therabel : drug (2012)</li> </ul> <p>No additional information for the 2013 January - May period has been submitted</p>
Windecker Stephan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Antiplatelet drug (2012)</li> <li>- Eli Lilly : Antiplatelet drug (2012)</li> <li>- Abbott : Stent (2012)</li> <li>- Biosensors : Stent (2012)</li> </ul>

## Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Windecker Stephan	<ul style="list-style-type: none"> <li>- Boston Scientific : Stent (2012)</li> <li>- Medtronic : Stent (2012)</li> <li>- Biotronik : Stent (2012)</li> <li>- Cordis : Stent (2012)</li> <li>- Edwards Lifesciences : TAVI (2012)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- St Jude Medical : OCT (2012)</li> <li>- Abbott : Stent (2012)</li> <li>- Biosensors : Stent (2012)</li> <li>- Medtronic : Stent (2012)</li> <li>- Biotronik : Stent (2012)</li> <li>- Cordis : Stent (2012)</li> </ul> <p>No additional information for the 2013 January - May period has been submitted</p>
Zamorano Gomez Jose Luis	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Abbott Vascular : Help in Design Echocardiographic protocol (2012)</li> <li>- Merck Sharp &amp; Dohme : Lecture (2012)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- FP7 EU research program : CV Imaging (2012)</li> </ul> <p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> <li>- Springer : ESC Textbook of CV Imaging (2012)</li> </ul>

## Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Zamorano Gomez Jose Luis	<p><b>Additional Information declared</b> 'XYWUfYX'z'f'&amp;\$% '&gt;Ubi Ufmi!' A Um</p> <p>13/05/2013      Same</p>

This table represents the relevant relationships of the above experts with Industries and other entities that were reported to us at the time of publication of the Guidelines.